Bosh sahifaPRE • NASDAQ
add
Prenetics Global Ltd
Yopilish kursi
4,50 $
Kunlik diapazon
4,43 $ - 4,43 $
Yillik diapazon
2,85 $ - 7,84 $
Bozor kapitalizatsiyasi
53,16 mln USD
Oʻrtacha hajm
6,93 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(USD) | iyn, 2024info | Y/Y qiyosi |
---|---|---|
Daromad | 5,94 mln | 4,32% |
Joriy xarajat | 14,38 mln | 0,52% |
Sof foyda | -10,72 mln | 50,83% |
Sof foyda marjasi | -180,46 | 52,87% |
Har bir ulushga tushum | — | — |
EBITDA | -9,51 mln | 13,59% |
Amaldagi soliq stavkasi | 0,79% | — |
Balans
Jami aktivlari
Jami passivlari
(USD) | iyn, 2024info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 63,89 mln | -67,46% |
Jami aktivlari | 233,31 mln | -16,93% |
Jami passivlari | 42,30 mln | -30,22% |
Umumiy kapital | 191,00 mln | — |
Tarqatilgan aksiyalar | 12,22 mln | — |
Narxi/balansdagi bahosi | 0,29 | — |
Aktivlardan daromad | -11,12% | — |
Kapitaldan daromad | -13,33% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(USD) | iyn, 2024info | Y/Y qiyosi |
---|---|---|
Sof foyda | -10,72 mln | 50,83% |
Operatsiyalardan naqd pul | — | — |
Sarmoyadan naqd pul | — | — |
Moliyadan naqd pul | — | — |
Naqd pulning sof oʻzgarishi | — | — |
Boʻsh pul | — | — |
Haqida
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer.
Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions.
The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
Tashkil etilgan
2014
Sayt
Xodimlar soni
322